Drug Trial Radar · NCT04422366
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Last checked: Nov 19, 2026Latest source record: Jun 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
8,000
Planned (sponsor's estimate)
Start
Apr 28, 2020
Primary completion
Sep 15, 2027
Study completion Sep 15, 2029
Sponsor
- Lead sponsor
- Shanghai Bovax Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 20 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years .
Conditions
- Cervical Cancer
- Vulvar Cancer
- Vaginal Cancer
- CIN1
- CIN2
- CIN3
- VaIN1
- VaIN2
- VaIN3
- Genital Wart
- VIN 1
- VIN 2
- VIN 3
- AIS
Interventions
9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)Biological
Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
GARDASIL®Biological
Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule
Primary outcomes
What the sponsor says the trial is designed to measure.
- The person-year incidence of HPV 31-, 33-, 45-, 52-, and 58-related high-grade cervical abnormalities (CIN 2/3) at least 1 month post Dose 3Time frame: 1 month post vaccination 3 (Month 7) up to Month 84
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Liuzhou center for disease control and prevention
Liuzhou, Guangxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.